Viking Therapeutics Equity 2024

Viking Therapeutics Aktienanalyse

What does Viking Therapeutics do?

Viking Therapeutics Inc. is a biotechnology company specializing in the development of drugs for the treatment of metabolic and endocrine disorders. It was founded in 2012 by Brian Lian, Ph.D., and is headquartered in San Diego, California. The company's business model focuses on targeting liver X receptors (LXRs) for the treatment of metabolic disorders. Viking Therapeutics aims to develop treatment options for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as osteoporosis and hypothyroidism. Their lead products in development are VK2809 for NAFLD/NASH and VK5211 for osteoporosis. The company has a promising product pipeline and aims to improve the lives of millions of patients. Viking Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Viking Therapeutics's Equity

Viking Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Viking Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Viking Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Viking Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Viking Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Viking Therapeutics Stock

What is the equity of Viking Therapeutics this year?

Viking Therapeutics has equity of 348.42 M USD this year.

What was the equity of Viking Therapeutics compared to the previous year?

The equity of Viking Therapeutics has increased/decreased by 139.79% increased compared to the previous year.

What impact does a high equity have on investors of Viking Therapeutics?

A high equity is advantageous for investors of Viking Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Viking Therapeutics?

A low equity can be a risk for investors of Viking Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Viking Therapeutics affect the company?

An increase in equity of Viking Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Viking Therapeutics affect the company?

A reduction in equity of Viking Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Viking Therapeutics?

Some factors that can affect the equity of Viking Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Viking Therapeutics so important for investors?

The equity of Viking Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Viking Therapeutics take to change the equity?

To change equity, Viking Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Viking Therapeutics pay?

Over the past 12 months, Viking Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Viking Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Viking Therapeutics?

The current dividend yield of Viking Therapeutics is .

When does Viking Therapeutics pay dividends?

Viking Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Viking Therapeutics?

Viking Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Viking Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Viking Therapeutics located?

Viking Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Viking Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Viking Therapeutics from 5/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Viking Therapeutics pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of Viking Therapeutics in the year 2023?

In the year 2023, Viking Therapeutics distributed 0 USD as dividends.

In which currency does Viking Therapeutics pay out the dividend?

The dividends of Viking Therapeutics are distributed in USD.